Kelly Bree, M.D.
Department of Urology, Division of Surgery
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Voluntary Clinical Assistant Professor, The University of Houston Tilman J. Fertitta Family College of Medicine, Houston, TX
Assistant Professor, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Ongoing Research Support 2921-0782-MOD003 Bree (PI) Sexual Function in Women after Radical Cystectomy The goal of this study is to asses characterize pre-operative sexual function and interest in sexual activity among women undergoing radical cystectomy. The study also aims to identify patient understanding and expectations as they relate to sexual dysfunction after radical cystectomy
Education & Training
Degree-Granting Education
| 2014 | George Washington University School of Medicine, Washington, DC, US, MD |
| 2010 | Lehman College, Bronx, New York, US, Education, Master of Education |
| 2008 | University of Miami, Gables, Florida, US, Biochemistry, BS |
Postgraduate Training
| 2020-2022 | Clinical Fellowship, Urologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2019 | Clinical Residency, Urology, University of California Medical Center, San Diego, California |
| 2014-2015 | Clinical Internship, General Surgery, University of California Medical Center, San Diego, California |
Licenses & Certifications
| 2022 | DEA |
| 2020 | Texas Medical Board |
| 2016 | Medical Board California |
Experience & Service
Faculty Academic Appointments
Fellow/Clinical Specialist, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Medical Staff, Department of Urology, The University of Texas MD Anderson Cancer Center, Van Nuys, CA, 2019 - 2020
Urologist, Department of Urology, Assuta Medical Group, North Hollywood, CA, 2019 - 2020
Administrative Appointments/Responsibilities
Medical Director, Department of Advanced Practice Provider Programs, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Associate Fellowship Program Director, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Other Professional Positions
Department of Urology APP Faculty Liaison, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2024
Chief Resident, Urologic Surgery, University of California San Diego Medical Center, San Diego, CA, 2018 - 2019
Resident, Urologic Surgery, University of California San Diego Medical Center, San Diego, CA, 2015 - 2018
Intern, General Surgery, University of California San Diego Medical Center, San Diego, CA, 2014 - 2015
Intramural Institutional Committee Activities
Committee Member, Bladder Cancer Support Center Research Steering Committee, The University of Texas MD Anderson Cancer Center
Committee Member, Bladder Cancer Support Center Steering Committee, The University of Texas MD Anderson Cancer Center
Honors & Awards
| 2024 | AUA Robotic Theater Rising Star |
| 2023 | Journal of Urology's Most Impactful Article of the Year Winner |
| 2023 | Physicians Referral Service Top Performer (Top 10th percentile nationally) |
| 2022 | British Journal of Urology International Reviewer of the Month |
| 2022 | Most Impactful Article of 2022, Journal of Urology |
| 2022 | South Central Section AUA Fellow Essay Competition Winner |
| 2021 | AUA Quality Improvement Summit Scholar |
| 2017 | American Urogynecologic Society Resident Scholar |
| 2017 | Earl F. Nation Western Section, AUA Resident Scholarship Recipient |
| 2017 | Rodney Appell Traveling Preceptorship, SUFU |
| 2017 | Society of Urodynamics, Female Pelvic Medicine, and Urogential Reconstruction Research Foundation Resident Nominee |
| 2016 | Outstanding AUA In-Service Award |
| 2014 | Kane-King-Dodek Obstetrical Honor Society Inductee |
| 2014 | Salman O. Kazmi, MD Memorial Urology Award Recipient |
| 2011 | Gill Fellowship Award Recipient |
| 2011 | ISCOPES Most Valuable Participant |
| 2008 | Iron Arrow Honor Society - highest honor, University of Miami |
| 2008 | Pan-Hellenic President of the Year - awarded for the role as President of Delta Phi Epsilon Sorority |
| 2006 - 2008 | Dean's List |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2022. Apixaban versus Enoxaparin for Post-Surgical DVT Prophylaxis. Conference. Apixaban versus Enoxaparin for Post-Surgical DVT Prophylaxis, US.
- 2022. Apixaban versus Enoxaparin for Post-Surgical DVT Prophylaxis. Conference. Apixaban versus Enoxaparin for Post-Surgical DVT Prophylaxis, US.
National Presentations
- 2024. Opportunities for Young Career Surgeons to Improve Outcomes. Conference. Opportunities for Young Career Surgeons to Improve Outcomes. Las Vegas, NV, US.
- 2024. Female Sexual Health in the Management of Bladder Cancer. Conference. Female Sexual Health in the Management of Bladder Cancer. Steamboat Springs, CO, US.
- 2023. Female Sexual Health in Bladder Cancer Management-Debunking Myths and Areas for Improvement. Conference. Female Sexual Health in Bladder Cancer Management-Debunking Myths and Areas for Improvement. Austin, TX, US.
- 2023. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in Largest Equal Access Health System in the US: The Veterans Affairs Health System (podium presentation). Conference. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in Largest Equal Access Health System in the US: The Veterans Affairs Health System (podium presentation). Austin, TX, US.
- 2023. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in Largest Equal Access Health System in the US: The Veterans Affairs Health System (podium presentation). Conference. Disparities in Stage at Diagnosis Among Black Bladder Cancer Patients in Largest Equal Access Health System in the US: The Veterans Affairs Health System (podium presentation). Chicago, IL, US.
- 2023. Female Sexual Health in Bladder Cancer Management. Conference. Female Sexual Health in Bladder Cancer Management. Austin, TX, US.
- 2022. Management, Surveillance Patterns and Costs Associated with Low-grade Papillary (Ta) Non-muscle Invasive Bladder Cancer (podium presentation). Conference. Management, Surveillance Patterns and Costs Associated with Low-grade Papillary (Ta) Non-muscle Invasive Bladder Cancer (podium presentation). San Diego, CA, US.
- 2022. Management, surveillance patterns and costs associated with low-grade papillary (Ta) non-muscle invasive bladder cancer (poster presentation). Conference. Management, surveillance patterns and costs associated with low-grade papillary (Ta) non-muscle invasive bladder cancer (poster presentation). New Orleans, LA, US.
- 2022. Management, surveillance patterns and costs associate with low-grade papillary (Ta) non-muscle invasive bladder cancer (accepted for poster). Conference. Management, surveillance patterns and costs associate with low-grade papillary (Ta) non-muscle invasive bladder cancer (accepted for poster). Amsterdam, Netherland, US.
- 2022. Management, surveillance patterns and costs associate with low-grade papillary (Ta) non-muscle invasive bladder cancer (accepted for poster). Conference. Management, surveillance patterns and costs associate with low-grade papillary (Ta) non-muscle invasive bladder cancer (accepted for poster). San Francisco, CA, US.
- 2022. Management, surveillance patterns and costs associated with low-grade papillary (Ta) non-muscle invasive bladder cancer (podium presentation ). Conference. Management, surveillance patterns and costs associated with low-grade papillary (Ta) non-muscle invasive bladder cancer (podium presentation ). San Diego, CA, US.
- 2021. Response to neoadjuvant chemotherapy and oncologic outcomes in muscle invasive bladder cancer with variant histologic differentiation (poster presentation). Conference. Response to neoadjuvant chemotherapy and oncologic outcomes in muscle invasive bladder cancer with variant histologic differentiation (poster presentation). Orlando, FL, US.
- 2021. Repeat transurethral resection (ReTURBT) of muscle invasive bladder cancer rior to radical cystectomy is prognostic but not therapeutic: a propensity-score matched analysis. (poster presentation at SUO Annual Meeting). Conference. Repeat transurethral resection (ReTURBT) of muscle invasive bladder cancer rior to radical cystectomy is prognostic but not therapeutic: a propensity-score matched analysis. (poster presentation at SUO Annual Meeting). Orlando, FL, US.
- 2021. A novel nomogram to predict BCG response in patient with high-grade NMIBC (accepted for poster presentation). Conference. A novel nomogram to predict BCG response in patient with high-grade NMIBC (accepted for poster presentation). Las Vegas, NV, US.
- 2021. UTUC surveillance following BCG-treated NMIBC: timing and risk factors associated with recurrence (accepted for poster presentation). Conference. UTUC surveillance following BCG-treated NMIBC: timing and risk factors associated with recurrence (accepted for poster presentation). Las Vegas, NV, US.
- 2021. All high grade NMIBC is high risk: BCG response in HG Ta tumors (accepted for podium presentation). Conference. All high grade NMIBC is high risk: BCG response in HG Ta tumors (accepted for podium presentation). Las Vegas, NV, US.
- 2021. All high grade NMIBC is high risk: BCG response in HG Ta tumors (accepted for podium presentation). Conference. All high grade NMIBC is high risk: BCG response in HG Ta tumors (accepted for podium presentation), US.
- 2021. Light-activated molecular nanomachines kill bladder cancer cells (virtual presentation). Conference. Light-activated molecular nanomachines kill bladder cancer cells (virtual presentation), US.
- 2020. Impact of sex on response to Bacillus Calmette-Guerin in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center (virtual presentation). Conference. Impact of sex on response to Bacillus Calmette-Guerin in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center (virtual presentation), US.
- 2020. Impact of UTUC on outcomes of non-muscle invasive bladder cancer treated with intraversical Bacillus Calmette-Guerin. (oral presentation). Conference. Impact of UTUC on outcomes of non-muscle invasive bladder cancer treated with intraversical Bacillus Calmette-Guerin. (oral presentation), US.
- 2020. Time interval from transurethral resection of bladder tumor to onset of BDG induction dose not impact therapeutic response: implication during times of impaired access to healthcare (poster presentation and virtual). Conference. Time interval from transurethral resection of bladder tumor to onset of BDG induction dose not impact therapeutic response: implication during times of impaired access to healthcare (poster presentation and virtual), US.
- 2020. Radical cystectomy and perioperative sexual function: a cross-sectional analysis (poster and virtual presentation). Conference. Radical cystectomy and perioperative sexual function: a cross-sectional analysis (poster and virtual presentation), US.
- 2020. Restaging transurethral resection of high-grade Ta urothelial carcinoma: a risk-adopted approach. (poster and virtual presentation). Conference. Restaging transurethral resection of high-grade Ta urothelial carcinoma: a risk-adopted approach. (poster and virtual presentation), US.
- 2019. Post-operative urinary tract infections: timing and uropathogens (podium presentation). Conference. Post-operative urinary tract infections: timing and uropathogens (podium presentation). Chicago, IL, US.
- 2018. A novel technique for surgical management of large-volume BPH (round table discussion). Conference. A novel technique for surgical management of large-volume BPH (round table discussion). Maui, HI, US.
- 2018. Lower urinary tract symptoms (LUTS) and mortality risk among older U.S. men: the Osteoporotic Fractures in Men(MrOS) Study. Conference. Lower urinary tract symptoms (LUTS) and mortality risk among older U.S. men: the Osteoporotic Fractures in Men(MrOS) Study. San Francisco, CA, US.
- 2018. Influence in genetic variation in the eandrogen receptor of te risk of cardiovascular disease in hypogonadal men (oral presentation). Conference. Influence in genetic variation in the eandrogen receptor of te risk of cardiovascular disease in hypogonadal men (oral presentation). San Francisco, CA, US.
- 2017. Influence of genetic variation in the androgen receptor on the risk of cardiovascular disease in hypogonadal men (podium presentation). Conference. Influence of genetic variation in the androgen receptor on the risk of cardiovascular disease in hypogonadal men (podium presentation). San Antonio, TX, US.
- 2017. The Association Between Testosterone and Vitality: The role of genetic variation in the androgen receptor (oral presentation). Conference. The Association Between Testosterone and Vitality: The role of genetic variation in the androgen receptor (oral presentation). Vancouver, US.
- 2017. Urologic Trauma:How often are urologists involved? (podium presentation). Conference. Urologic Trauma:How often are urologists involved? (podium presentation), US.
- 2017. Potential Residency Training Factors That May Influence Decision to Pursue Pediatric Urology Fellowship (poster presentation). Conference. Potential Residency Training Factors That May Influence Decision to Pursue Pediatric Urology Fellowship (poster presentation), US.
- 2013. Genomic Study of Clinical Benign Prostatic Hyperplasia Specimens (poster presentation). Conference. Genomic Study of Clinical Benign Prostatic Hyperplasia Specimens (poster presentation). Boston, MA, US.
- 2012. What Can Training Programs Learn from the Literature When Starting a New or Refining on Established Curricullum (poster presentation). Conference. What Can Training Programs Learn from the Literature When Starting a New or Refining on Established Curricullum (poster presentation). Boston, MA, US.
- 2012. What Can Training Programs Learn from the Literature When Starting a New or Refining on Established Curriculum? (poster presentation). Conference. What Can Training Programs Learn from the Literature When Starting a New or Refining on Established Curriculum? (poster presentation), US.
International Presentations
- 2023. Age-, Sex- and Race-related Differences in Outcomes of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy: The Role of Biology versus Access to Standard Medical Care (poster presentation). Conference. Age-, Sex- and Race-related Differences in Outcomes of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy: The Role of Biology versus Access to Standard Medical Care (poster presentation). Chicago, US.
- 2023. Unfavorable Pathologic Outcome after Radical Cystectomy with Neoadjuvant Chemotherapy: What is the next Treatment?. Conference. Unfavorable Pathologic Outcome after Radical Cystectomy with Neoadjuvant Chemotherapy: What is the next Treatment?. Chicago, US.
Grant & Contract Support
| Title: | A Window of Opportunity Phase I Study of UGN-201 in Patients with Bladder Cancer Undergoing Radical Cystectomy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 2021-0630 |
| Title: | A Randomized Phase III Trial of Intravesical BCG versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | EA8212 |
| Title: | Sexual Function in Women after Radical Cystectomy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 2921-0782_MOD003 |
Selected Publications
Peer-Reviewed Articles
- Lobo, N, Lobo, N, Duan, Z, Duan, Z, Sood, A, Sood, A, Zhao, H, Zhao, H, Lindskrog, SV, Lindskrog, SV, Dyrskjøt, L, Dyrskjøt, L, Giordano, SH, Giordano, SH, Williams, SB, Williams, SB, Bree, KK, Bree, KK, Kamat, A, Kamat, A. Sex Disparity in Non-muscle-invasive Bladder Cancer. European Urology Oncology 8(3):608-611, 2025. e-Pub 2025. PMID: 39448349.
- Carriere, P, Alhalabi, O, Gao, J, Mohamad, O, Campbell, M, Shah, AY, Goswami, S, Bree, KK, Lee, B, Navai, N, Mok, H, Mayo, LL, Guo, CC, Nguyen, Q, McGuire, SE, Park, R, Shah, SJ, Hoffman, K, Frank, SJ, Tang, C, Choi, S, Kamat, A, Hassanzadeh, CJ. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clinical and Translational Radiation Oncology 49, 2024. e-Pub 2024. PMID: 39403573.
- Lobo N, Duan Z, Sood A, Tan WS, Grajales V, Contieri R, Lindskrog SV, Dyrskjøt L, Zhao H, Giordano SH, Williams SB, Bree KK, Kamat AM. Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities?. Eur Urol Oncol 7(5):1069-1079, 2024. e-Pub 2024. PMID: 38302322.
- Bree, KK, Janes, JL, Hensley, PJ, Srinivasan, A, De Hoedt, AM, Das, S, Freedland, S, Williams, SB. Racial disparities in stage at bladder cancer diagnosis in the US Veterans Affairs healthcare system. BJU international 134(3):473-483, 2024. e-Pub 2024. PMID: 38680113.
- Contieri R, Tan WS, Grajales V, Hensley PJ, Martini A, Bree K, Myers A, Nogueras-Gonzalez G, Navai N, Dinney CP, Guo C, Kamat AM. Influence of Lamina Propria Invasion Extension on T1 High-grade Non-muscle-invasive Bladder Cancer in Patients Undergoing BCG or Radical Cystectomy. BJU Int 133(6):733-741, 2024. e-Pub 2024. PMID: 38374533.
- Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-term Oncological Outcomes in Patients Diagnosed with Non-metastatic Plasmacytoid Variant of Bladder Cancer: A 20-year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):241-255, 2024. e-Pub 2024. PMID: 37922370.
- Contieri R, Grajales V, Tan WS, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras-Gonzalez GM, Guo CC, Navai N, Dinney CP, Kamat AM. Impact of Age >70 Years on Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. BJU Int 133(1):63-70, 2024. e-Pub 2024. PMID: 37442564.
- Contieri R, Hensley PJ, Tan WS, Grajales V, Bree K, Nogueras-Gonzalez GM, Lee BH, Navai N, Dinney CP, Kamat AM. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol 6(6):590-596, 2023. e-Pub 2023. PMID: 37558542.
- Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Guérin (BCG) Unresponsive Non-Muscle-Invasive Bladder Cancer: Are the Subgroups Equal?. BJU Int 132(4):384-386, 2023. e-Pub 2023. PMID: 37246493.
- Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol 6(5):531-534, 2023. e-Pub 2023. PMID: 37468392.
- Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but not Therapeutic. Reply. J Urol 210(2):101097JU0000000000003553, 2023. e-Pub 2023. PMID: 37211780.
- Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-Muscle-Invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 13(53):16-22, 2023. e-Pub 2023. PMID: 37441349.
- Wang XS, Bree KK, Navai N, Kamal M, Shen SE, Letona E, Cleeland CS, Shi Q, Gottumukkala V. Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37297013.
- Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk from Second Primary Malignancy in Bladder Cancer Patients following Radical Cystectomy: Implications for Survivorship. Urol Oncol 41(2):108.e11-108.e17, 2023. e-Pub 2023. PMID: 36404232.
- Bree KK, Kokorovic A, Westerman ME, Hensley PJ, Brooks NA, Qiao W, Shen Y, Kamat AM, Dinney CP, Navai N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but not Therapeutic. J Urol 209(1):140-149, 2023. e-Pub 2023. PMID: 36250944.
- Wang XS, Bree KK, Navai N, Kamal M, S-E S, Letona E, Cleland CS, Shi Q, Gottumukkala V. Utility of Patient-reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers 15(11):3051, 2023. e-Pub 2023.
- Faulk A, Avulova S, Bree KK, Baak-Kukreja J, Westerman ME. Pelvic Organ Preservation in Non-muscle Invasive Bladder Cancer: Less is More. Eur Urol Focus S2405-4569(23):00103-7, 2023. e-Pub 2023.
- Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk for Second Primary Malignancy in Bladder Cancer Patients Following Radical Cystectomy: Implications for Survivorship. Urol Oncol 41(2):108e11-108.317, 2023. e-Pub 2023. PMID: 36404232.
- Hensley PJ, Bree KK, Guo CC, Lobo N, Campbell MT, Pettaway CA, Kamat AM. Clinicopathological Analysis and Outcomes of Inflammatory Myofibroblastic Tumours of the Urinary Bladder. BJU Int 130(5):604-610, 2022. e-Pub 2022. PMID: 34773684.
- Hensley PJ, Duan Z, Bree K, Sood A, Zhao H, Lobo N, Contieri R, Campbell MT, Guo CC, Navai N, Williams SB, Dinney CP, Kamat AM. Competing Mortality Risk from Secondary Primary Malignancy in Bladder Cancer Patients following Radical Cystectomy: Implications for Survivorship. Urol Oncol S1078-2439(22):00393-3. e-Pub 2022. PMID: 36404232.
- Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
- Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Should Patients with Non-Muscle-Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors during Bacille Calmette-Guérin?. BJU Int 130(4):463-469, 2022. e-Pub 2022. PMID: 34854189.
- Lobo N, Bree KK, Hensley PJ, Nogueras-Gonzalez GM, Abraham P, Navai N, Dinney CP, Kamat AM. Reduced-dose Bacillus Calmette-Guérin (BCG) in an Era of BCG Shortage: Real-world Experience from a Tertiary Cancer Centre. BJU Int 130(3):323-330, 2022. e-Pub 2022. PMID: 34847263.
- Escott M, Avulova S, Bree K, Westerman ME. Radical Cystectomy and Women's Sexual Health - Can we do Better?. Curr Opin Urol 32(5):545-553, 2022. e-Pub 2022. PMID: 35916011.
- Kamal M, Navai N, Bree KK, Williams LA, Cleeland CS, Shen SE, Wang XS. Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting. Cancers (Basel) 16(14):3896, 2022. e-Pub 2022. PMID: 36010890.
- Bree KK, Hensley PJ, Lobo N, Brooks NA, Nogueras-Gonzalez GM, Guo CC, Navai N, Grossman HB, Dinney CP, Kamat AM. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J Urol 208(2):284-291, 2022. e-Pub 2022. PMID: 35770498.
- Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol 5(3):347-356, 2022. e-Pub 2022. PMID: 33935020.
- Bree KK, Shan Y, Hensley PJ, Lobo N, Hu C, Tyler DS, Chamie K, Kamat AM, Williams SB. Management, Surveillance Patterns, and Costs Associated with Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Netw Open 5(3):e223050, 2022. e-Pub 2022. PMID: 35302627.
- Lobo N, Hensley PJ, Bree KK, Nogueras-Gonzalez GM, Navai N, Dinney CP, Sylvester RJ, Kamat AM. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. Eur Urol Oncol 5(1):84-91, 2022. e-Pub 2022. PMID: 34920986.
- Bree KK, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Reply. J Urol 207(2):476-477, 2022. e-Pub 2022. PMID: 34694162.
- Hensely PJ, Lobo N Bree KK, Tan WS, Gontero P, Williams SB, Guo CG, Giannarini G, Dyrskjot L, Kamat AM. Predictive Biomarkers in the Management of Bladder Cancer: Perspective in an Evolving Therapeutic Landscape. Societe Internationale d'Urologie Journal 3(4):245-257, 2021. e-Pub 2021.
- Bree KK, Hensley PJ, Brooks N, Matulay J, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Impact of Sex on Response to BCG in Non-Muscle Invasive Bladder Cancer Patients: A Contemporary Review from a Tertiary Care Center. World J Urol 39(11):4143-4149, 2021. e-Pub 2021. PMID: 34117914.
- Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):1267, 2021. e-Pub 2021. PMID: 34372685.
- Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumour to Bacille Calmette-Guérin Induction does not Impact Therapeutic Response. BJU Int 128(5):634-641, 2021. e-Pub 2021. PMID: 33783950.
- Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):1258-1267, 2021. e-Pub 2021. PMID: 34184926.
- Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CPN, Kamat AM. Impact of Upper Tract Urothelial Carcinoma on Response to BCG in Patients with Non-Muscle-Invasive Bladder Cancer. BJU Int 128(5):568-574, 2021. e-Pub 2021. PMID: 33484074.
- Westerman ME, Bree KK, Kokorovic A, Frank J, Wang XS, Kamat AM, Dinney CPN, Navai N. What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology 157:181-187, 2021. e-Pub 2021. PMID: 34186127.
- Bree KK, Hensley PJ, Westerman ME, Kokorovic A, Nogueras-Gonzalez GM, Dinney CP, Kamat AM, Navai N. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. J Urol 206(3):577-585, 2021. e-Pub 2021. PMID: 33872050.
- Panizzon MS, Bree K, Hsieh C, Hauger R, Xian H, Jacobson K, Lyons MJ, Franz CE. Genetic Variation in the Androgen Receptor Modifies the Association between Testosterone and Vitality in Middle-aged Men. J Sex Med 17(12):2351-2361, 2020. e-Pub 2020.
- Gaylis F, Bree KK, Dato P, Andriole GL, Kane CJ, Kader AK. Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples from Clinical Practice. Rev Urol 22(4):152-158, 2020. e-Pub 2020. PMID: 33927572.
- Ghali F, Elbakry AA, Hamilton ZA, Yik K, Nassrei R, Patel S, Eldefrawy A, Ryan S, Bradshaw AW, Meagher M, Bree K, Reddy M, Lee HJ, Derweesh IH. Robotic Partial Nephrectomy for Clinical T2a Renal Mass is Associated with Improved Trifecta Outcome Compared to Open Partial Nephrectomy: A Single Surgeon Comparative Analysis. World J Urol 38(5):1113-1122, 2020. e-Pub 2020.
- Patel SH, Panian J Bree K, Derweesh I, Millard F, Randall J, McKay R. Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. Eur Urol Focus 6(1):17-25, 2020. e-Pub 2020.
Review Articles
- MacDonald, LP, Smith, MR, Bree, KK. New Paradigms for Bladder Cancer Management in Geriatrics. Clinics in Geriatric Medicine 41(2):175-185, 2025. e-Pub 2025. PMID: 40345772.
- Li, R, Hensley, PJ, Gupta, S, Al Ahmadie, H, Babjuk, M, Black, P, Brausi, M, Bree, KK, Fernandez, M, Guo, CC, Horowitz, A, Lamm, DL, Lerner, SP, Lotan, Y, Mariappan, P, McConkey, D, Mertens, LS, Mir, C, Ross, JS, O'Donnell, M, Palou, J, Pohar, KS, Steinberg, GD, Soloway, M, Spiess, PE, Svatek, RS, Tan, WS, Taoka, R, Buckley, R, Kamat, A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European urology 86(6):516-527, 2024. e-Pub 2024. PMID: 39183090.
- Faulk A, Avulova S, Bree KK, Baak-Kukreja J, Westerman ME. Pelvic Organ Preservation in Non-Muscle-Invasive Bladder Cancer: Less Is More. Eur Urol Focus 9(4):571-574, 2023. e-Pub 2023. PMID: 37142535.
- Bree KK, Hensley PJ, Pettaway CA. Germline Mutations in African American Men with Prostate Cancer: Incidence, Implications and Diagnostic Disparities. Urology 163:148-155, 2022. e-Pub 2022. PMID: 34453957.
- Bree, KK, Henley, PJ, Pettaway, CA. Germline Predisposition to Prostate Cancer in Diverse Populations. Urologic Clinics of North America 48(3):411-423, 2021. e-Pub 2021. PMID: 34210495.
- Bree, KK, Brooks, NA, Kamat, A. Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America 35(3):513-529, 2021. e-Pub 2021. PMID: 33958148.
- Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK. Germline Genetics in Localized Prostate Cancer. Curr Opin Urol 29(4):326-333, 2019. e-Pub 2019. PMID: 31116139.
Professional Educational Materials
- Bree KK, Whicker SA, Fromme HB, Paik S, Greenberg L. What Can Programs Learn from the Literature When Starting a New or Refining an Established Curriculum. Residents as Teachers (RAT), 2014.
Editorials
- Kamat AK, Hensley PJ, Bree KK. Occult Nodal Metastases in Patients Down-staged to Non-Muscle Invasive Disease Following Neoadjuvant Chemotherapy. In Practice Update, 2020.
- Bree KK, Matin SF. The Remaining Ipsilateral Ureteral Orifice Provokes Intravesical Tumor Recurrence after Nephrouretectomy of Upper Tract Urothelial Carcinoma: A Multicenter Study with a Mid-term Follow-up. Urology:145:171. doi: 10.1016/j.urology.2020.06.086, 2020.
Book Chapters
- Lange S, Grajales V, Bree K. Gynecologic Care of the Cancer Patient. In: Gynecologic Cancer. Cambridge Press, 2022.
- Bree KK, Brooks NA, Kamat AM. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. In: Bladder Cancer. 35. Hematol Oncol Clin North Am, 513-529, 2021.
- Bree KK, Hensley PJ, Pettaway CA. Germline Predisposition to Prostate Cancer in Diverse Populations. In: Urol Clin North Am. 3, 411-423, 2021.
- Bree KK, Santiago-Lastra Y. Diabetic Cystopathy. In: Urologic Care for Patients with Progressive Neurological Conditions. Springer, 159-166, 2019.
Letters to the Editor
- Myers, AA, Tan, WS, Grajales, V, Hwang, H, Bree, KK, Navai, N, Lee, B, Dinney, CP, Kamat, A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer. European urology 86: 366-368, 2024.
- Bree, KK, Navai, N. Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply. Journal of Urology 210: 839, 2023.
- Bree, KK, Hensley, PJ, Lobo, N, Brooks, NA, Nogueras Gonzalez, G, Guo, CC, Navai, N, Barton Grossman, H, Dinney, CP, Kamat, A. Reply by Authors. Journal of Urology 208: 290-291, 2022.
Patient Reviews
CV information above last modified October 30, 2025